Legend Biotech (LEGN) Stock Price

Legend Biotech Price

NASDAQ·CLOSED
18.55USD-0.50 (-2.66 %)
Market closed

Revenue has compounded at 60.3% per year over the past 8 years to 1.03 B USD. Legend Biotech's net margin stands at -28.8%, up from -586.4% several years earlier. Analysts set a median price target of 72.42 USD, implying 290.4% above the current price. Of 25 analysts, 22 rate the stock a buy — an overall Buy consensus. The stock trades about 11% above its 52-week low.

Legend Biotech stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Legend Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Legend Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Legend Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Legend Biotech Stock Price History
DateLegend Biotech Price
7/31/202618.55 USD
7/30/202619.05 USD
7/29/202618.83 USD
7/27/202618.85 USD
7/23/202623.53 USD
7/22/202623.53 USD
7/21/202623.54 USD
7/20/202623.21 USD
7/17/202622.26 USD
7/16/202622.71 USD
7/15/202623.04 USD
7/14/202625.67 USD
7/13/202625.73 USD
7/10/202627.08 USD
7/9/202627.38 USD
7/8/202628.12 USD
7/7/202627.68 USD
7/6/202628.21 USD
7/2/202629.91 USD
7/1/202629.89 USD
6/30/202628.88 USD
6/29/202628.60 USD
6/26/202628.69 USD
6/25/202628.43 USD
6/24/202629.38 USD
6/23/202629.30 USD
6/22/202628.82 USD
6/18/202628.85 USD
6/17/202633.26 USD
6/16/202633.54 USD
6/15/202635.28 USD
6/12/202635.63 USD
6/11/202635.37 USD
6/10/202633.08 USD
6/9/202633.49 USD
6/8/202631.52 USD
6/5/202633.92 USD
6/4/202634.53 USD
6/3/202635.01 USD
6/2/202634.27 USD
6/1/202625.71 USD
5/29/202627.14 USD
5/28/202629.12 USD
5/27/202629.19 USD
5/26/202629.52 USD
5/22/202629.35 USD
5/21/202628.03 USD
5/20/202627.56 USD
5/19/202626.94 USD
5/18/202626.98 USD
5/15/202627.55 USD
5/14/202628.60 USD
5/13/202628.67 USD
5/12/202628.26 USD
5/11/202625.58 USD
5/8/202628.12 USD
5/7/202628.57 USD
5/6/202628.96 USD
5/5/202628.51 USD
5/4/202626.50 USD
5/1/202623.59 USD
4/30/202623.52 USD
4/29/202622.77 USD
4/28/202623.56 USD
4/27/202623.65 USD
4/24/202623.90 USD
4/23/202623.99 USD
4/22/202625.93 USD
4/21/202625.22 USD
4/20/202625.07 USD
4/17/202621.17 USD
4/16/202621.08 USD
4/15/202620.52 USD
4/14/202618.69 USD
4/13/202617.69 USD
4/10/202618.16 USD
4/9/202618.20 USD
4/8/202618.30 USD
4/7/202617.99 USD
4/6/202618.68 USD
4/2/202619.14 USD
4/1/202619.05 USD
3/31/202618.09 USD
3/30/202617.31 USD
3/27/202616.80 USD
3/26/202617.49 USD
3/25/202617.60 USD
3/24/202617.09 USD
3/23/202617.23 USD
3/20/202617.41 USD
3/19/202617.87 USD
3/18/202618.21 USD
3/17/202618.55 USD
3/16/202619.10 USD
3/13/202618.75 USD
3/12/202619.05 USD
3/11/202620.27 USD
3/10/202619.56 USD
3/9/202619.14 USD
3/6/202618.97 USD
3/5/202617.75 USD
3/4/202617.85 USD
3/3/202617.86 USD
3/2/202618.44 USD
2/27/202619.00 USD
2/26/202619.28 USD
2/25/202619.72 USD
2/24/202619.50 USD
2/23/202619.75 USD
2/20/202618.12 USD
2/19/202618.36 USD
2/18/202618.35 USD
2/17/202618.11 USD
2/13/202617.58 USD
2/12/202618.06 USD
2/11/202618.54 USD
2/10/202617.91 USD
2/9/202617.19 USD
2/6/202617.10 USD
2/5/202616.70 USD
2/4/202616.65 USD
2/3/202616.66 USD
2/2/202617.15 USD
1/30/202617.50 USD
1/29/202617.72 USD
1/28/202617.85 USD
1/27/202618.27 USD
1/26/202618.96 USD
1/23/202619.01 USD
1/22/202619.34 USD
1/21/202620.76 USD
1/20/202623.42 USD
1/16/202622.14 USD
1/15/202622.11 USD
1/14/202623.28 USD
1/13/202622.57 USD
1/12/202623.70 USD
1/9/202623.60 USD
1/8/202623.03 USD
1/7/202622.72 USD
1/6/202620.98 USD
1/5/202620.31 USD
1/2/202621.51 USD
12/31/202521.74 USD
12/30/202521.53 USD
12/29/202521.92 USD
12/26/202522.53 USD
12/24/202522.98 USD
12/23/202522.85 USD
12/22/202522.69 USD
12/19/202521.92 USD
12/18/202521.28 USD
12/17/202521.42 USD
12/16/202521.65 USD
12/15/202522.01 USD
12/12/202522.32 USD
12/11/202523.01 USD
12/10/202523.36 USD
12/9/202523.88 USD
12/8/202526.12 USD
12/5/202528.13 USD
12/4/202527.81 USD
12/3/202527.75 USD
12/2/202526.69 USD
12/1/202526.84 USD
11/28/202527.71 USD
11/26/202527.50 USD
11/25/202528.19 USD
11/24/202527.15 USD
11/21/202528.17 USD
11/20/202527.53 USD
11/19/202528.00 USD
11/18/202529.42 USD
11/17/202529.72 USD
11/14/202530.29 USD
11/13/202531.01 USD
11/12/202531.18 USD
11/11/202532.03 USD
11/10/202531.59 USD
11/7/202531.80 USD
11/6/202532.37 USD
11/5/202532.01 USD
11/4/202532.05 USD
11/3/202532.13 USD
10/31/202532.40 USD
10/30/202532.25 USD
10/29/202532.13 USD
10/28/202532.57 USD
10/27/202532.12 USD
10/24/202531.86 USD
10/23/202531.67 USD
10/22/202532.11 USD
10/21/202532.86 USD
10/20/202532.91 USD
10/17/202531.96 USD
10/16/202532.36 USD
10/15/202533.72 USD
10/14/202533.23 USD
10/13/202532.85 USD
10/10/202531.70 USD
10/9/202532.22 USD
10/8/202532.21 USD
10/7/202531.41 USD
10/6/202531.44 USD
10/3/202532.06 USD
10/2/202532.29 USD
10/1/202532.66 USD
9/30/202532.61 USD
9/29/202532.85 USD
9/26/202533.37 USD
9/25/202532.82 USD
9/24/202532.88 USD
9/23/202532.93 USD
9/22/202534.08 USD
9/19/202534.01 USD
9/18/202535.16 USD
9/17/202534.47 USD
9/16/202534.34 USD
9/15/202533.88 USD
9/12/202533.11 USD
9/11/202533.83 USD
9/10/202533.47 USD
9/9/202534.25 USD
9/8/202534.62 USD
9/5/202536.08 USD
9/4/202534.99 USD
9/3/202535.95 USD
9/2/202534.22 USD
8/29/202534.73 USD
8/28/202534.37 USD
8/27/202534.72 USD
8/26/202535.08 USD
8/25/202534.60 USD
8/22/202535.56 USD
8/21/202535.53 USD
8/20/202535.63 USD
8/19/202536.54 USD
8/18/202537.45 USD
8/15/202537.50 USD
8/14/202537.71 USD
8/13/202536.93 USD
8/12/202536.99 USD
8/11/202536.24 USD
8/8/202537.00 USD
8/7/202537.43 USD
8/6/202537.66 USD
8/5/202538.42 USD
8/4/202538.45 USD
Access this data via the Eulerpool API
Get Free API Key

Legend Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
285.14 M USD
-439.49 M USD
-518.25 M USD
Jan 1, 2024
627.24 M USD
-303.24 M USD
-177.03 M USD
Jan 1, 2025
1.03 B USD
-136.50 M USD
-296.80 M USD
Jan 1, 2026 (e)
1.43 B USD
-992.27 M USD
6.63 M USD
Jan 1, 2027 (e)
1.78 B USD
-1.24 B USD
295.82 M USD
Jan 1, 2028 (e)
2.04 B USD
-1.42 B USD
442.55 M USD
Jan 1, 2029 (e)
2.43 B USD
-1.68 B USD
499.21 M USD
Jan 1, 2030 (e)
2.81 B USD
-1.95 B USD
724.91 M USD

Legend Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 9:42 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
0.020.050.060.080.070.120.290.631.031.431.782.042.432.81
–113.0424.4922.95-9.3372.06143.59120.0063.9639.0124.4914.9018.6415.71
100.00100.00100.00100.00100.0043.5949.1262.5260.3160.3160.3160.3160.3160.31
0.020.050.060.080.070.050.140.390.620.861.071.231.461.69
0.01–-0.13-0.31-0.41-0.46-0.44-0.30-0.14-0.99-1.24-1.42-1.68-1.95
56.52-2.04-216.39-417.33-597.06-388.89-154.04-48.33-13.23-69.42-69.42-69.42-69.40-69.42
9.00-2.00-101.00-266.00-403.00-446.00-518.00-177.00-296.006.00295.00442.00499.00724.00
–-122.224,950.00163.3751.5010.6716.14-65.8367.23-102.034,816.6749.8312.9045.09
184.73100.00100.21132.36146.60159.04181.91182.85184.73184.73184.73184.73184.73184.73
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Legend Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Legend Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Legend Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Legend Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Legend Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Legend Biotech stock margins

The Legend Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Legend Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Legend Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-590.32 %
-586.38 %
Jan 1, 2022
44.14 %
-389.40 %
-381.48 %
Jan 1, 2023
49.42 %
-154.13 %
-181.75 %
Jan 1, 2024
62.60 %
-48.35 %
-28.22 %
Jan 1, 2025
60.34 %
-13.27 %
-28.85 %
Jan 1, 2026 (e)
60.34 %
-69.43 %
0.46 %
Jan 1, 2027 (e)
60.34 %
-69.43 %
16.63 %
Jan 1, 2028 (e)
60.34 %
-69.43 %
21.64 %

Legend Biotech Stock Revenue, EBIT, Earnings per Share

The Legend Biotech earnings per share therefore indicates how much revenue Legend Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.47 USD
-2.77 USD
-2.75 USD
Jan 1, 2022
0.74 USD
-2.86 USD
-2.81 USD
Jan 1, 2023
1.57 USD
-2.42 USD
-2.85 USD
Jan 1, 2024
3.43 USD
-1.66 USD
-0.97 USD
Jan 1, 2025
5.57 USD
-0.74 USD
-1.61 USD
Jan 1, 2026 (e)
3.87 USD
-5.37 USD
0.02 USD
Jan 1, 2027 (e)
4.82 USD
-6.69 USD
0.80 USD
Jan 1, 2028 (e)
5.54 USD
-7.69 USD
1.20 USD

Legend Biotech business model & stock analysis

Legend Biotech Corp is a leading biopharmaceutical company specializing in the discovery and development of innovative cell therapies for the treatment of serious diseases such as cancer. The company was founded in 2015 as a subsidiary of Genscript Biotech Corp and is headquartered in Somerset, New Jersey, USA. Additionally, the company also operates locations in China and Europe.

Legend Biotech SWOT Analysis

Strengths

Legend Biotech Corp possesses several key strengths that contribute to its success in the market. Notable strengths include:

  • Strong research and development capabilities: Legend Biotech Corp has a highly skilled R&D team that continues to drive innovation and develop cutting-edge biotechnology products.
  • Robust pipeline: The company has a diverse and promising pipeline of potential biopharmaceutical products, enabling potential future growth.
  • Strategic partnerships: Legend Biotech Corp has established strategic collaborations with reputable industry players, allowing access to additional resources, expertise, and distribution channels.
  • Strong financial position: The company has a solid financial foundation, providing stability and resources for ongoing operations and investment in future growth.

Weaknesses

Despite its strengths, Legend Biotech Corp also faces certain weaknesses that could hinder its growth and performance. These weaknesses include:

  • Limited global market presence: The company's market reach is relatively limited, primarily focused on specific regions and markets, which may impact its ability to capture a broader customer base.
  • Dependency on key products: A significant portion of Legend Biotech Corp's revenue is heavily reliant on a few key products, creating susceptibility to market fluctuations or the success of these specific products.
  • Regulatory challenges: The biotechnology industry faces rigorous regulations, and compliance with these regulations can be time-consuming and costly, potentially affecting product development timelines.

Opportunities

Legend Biotech Corp can leverage several opportunities to maximize its market potential and expand its operations. Key opportunities include:

  • Increasing demand for biopharmaceuticals: The global demand for biologic drugs continues to rise, presenting a significant growth opportunity for Legend Biotech Corp to capture market share.
  • Emerging markets: Expanding into emerging markets with growing healthcare systems can provide the company with access to a broader customer base and untapped revenue streams.
  • Technological advancements: The rapid advancement of technology in biotechnology can open up new possibilities for Legend Biotech Corp in terms of product development, efficiency, and cost-effectiveness.

Threats

Legend Biotech Corp also faces certain threats that pose challenges to its operations and market position. These threats include:

  • Intense competition: The biopharmaceutical industry is highly competitive, with numerous established players and new entrants, intensifying competition for market share and resources.
  • Patent expirations: The expiration of patents for certain products may lead to increased competition from generics and impact the company's market share and profitability.
  • Economic fluctuations: Economic downturns or instability may lead to reduced healthcare spending, which could affect the demand for Legend Biotech Corp's products.

Legend Biotech Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Legend Biotech Employees
Details
Date
Legend Biotech Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Legend Biotech Segments

Legend Biotech Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States of America
North America
China
Other Countries
Details
Date
United States of America
North America
China
Other Countries
Jan 1, 2020
0.00 USD
75.68 M USD
0.00 USD
0.00 USD
Jan 1, 2021
86.40 M USD
0.00 USD
3.42 M USD
0.00 USD
Jan 1, 2022
116.70 M USD
0.00 USD
328,000.00 USD
75,000.00 USD

Legend Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Legend Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Legend Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Legend Biotech shares outstanding

The number of shares of Legend Biotech was 184.73 M in 2025. This indicates how many shares Legend Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
146.60 M Stocks
Jan 1, 2022
159.04 M Stocks
Jan 1, 2023
181.91 M Stocks
Jan 1, 2024
182.85 M Stocks
Jan 1, 2025
184.73 M Stocks
Jan 1, 2026 (e)
184.73 M Stocks
Jan 1, 2027 (e)
184.73 M Stocks
Jan 1, 2028 (e)
184.73 M Stocks

Current Legend Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
2.74 %
Buy
88.00 % (22)
Hold
12.00 % (3)
Sell
0.00 % (0)
12M Price Target
72.42
Last Price
18.55
Currency
USD
12M Return Potential
290.40 %
LTM Return
0 %

Legend Biotech Analyst Rating Actions

DateFirmActionRatingReliability
7/28/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/27/2026
RBC Capital
RBC Capital
MaintainedOutperform52
7/24/2026
UBS
UBS
DowngradeBuyNeutral51
7/7/2026
RBC Capital
RBC Capital
MaintainedOutperform52
6/3/2026
UBS
UBS
MaintainedBuy51
6/3/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/18/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/13/2026
TD Cowen
TD Cowen
MaintainedHold60
5/13/2026
RBC Capital
RBC Capital
MaintainedOutperform52
5/13/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight60

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Legend Biotech Earnings Calls

2025

Legend Biotech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/20260.08USD-362.89 MUSD-2026 Q2
5/12/2026-0.02USD-313.18 MUSD-2026 Q1
3/10/2026-0.11USD-313.01 MUSD-2025 Q4
8/11/2025-0.15USD-233.57 MUSD-2025 Q2
11/18/2024-0.43USD-145.69 MUSD-2024 Q3
11/29/2022-0.35USD-30.29 MUSD-2022 Q2
8/28/2020-0.27USD-13.19 MUSD-2020 Q2

EESG©

Eulerpool ESG Scorecard© for the Legend Biotech stock

62/100
36
Environment
85
Social
65
Governance
E

Environment

20
Scope 1 - Direct Emissions770
Scope 2 - Indirect emissions from purchased energy12,427.69
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions13,197.69
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees32.48
Share of Asian management—
Percentage of Hispanic/Latino employees12.99
Hispano/Latino Management share—
Percentage of Black employees11.71
Black Management Share—
Percentage of white employees38.39
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Legend Biotech shareholder structure

% Name
6.95672%
FMR LLC
FMR LLC
2.08123%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
2.05237%
SUVRETTA CAPITAL MANAGEMENT, LLC
SUVRETTA CAPITAL MANAGEMENT, LLC
1.62016%
HHLR ADVISORS, LTD.
HHLR ADVISORS, LTD.
1.56031%
WESTFIELD CAPITAL MANAGEMENT CO LP
WESTFIELD CAPITAL MANAGEMENT CO LP
1.26822%
BLACKROCK, INC.
BLACKROCK, INC.
...

Legend Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
64.30%
of 5
of 5
SEC ↗
57.10%
GenScript Biotech Corporation
GenScript Biotech Corporation
SEC ↗
13.10%
FMR LLC
FMR LLC
SEC ↗
12.20%
Fangliang Zhang
Fangliang Zhang
SEC ↗
11.50%
GenScript Corporation
GenScript Corporation
SEC ↗
11.50%
AquaPoint L.P.
AquaPoint L.P.
SEC ↗
10.30%
Hillhouse Investment Management, Ltd.
Hillhouse Investment Management, Ltd.
SEC ↗
5.80%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
3.70%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
SEC ↗

Legend Biotech Executives and Management Board

14 members · avg. age 63 · 21 % women

Management

YH

Dr. Ying Huang (52)

Chief Executive Officer, Director · since 2019

–
CS

Mr. Carlos Santos

Chief Financial Officer

–
AB

Mr. Alan Bash

President - CARVYKTI

–

Board of Directors

FZ

Dr. Fangliang Zhang (60)

Chairman of the Board · since 2015

–
YW

Ms. Ye Wang (56)

Director · since 2015

–
JY

Ms. Jessie Yeung

Director · since 2025

–
LZ

Dr. Li Zhu (75)

Director

–
PC

Dr. Patrick Casey (69)

Independent Director

–
TH

Mr. Tomas Heyman (69)

Independent Director

–

Frequently asked questions about Legend Biotech

Legend Biotech Corp is a leading biopharmaceutical company that specializes in the discovery and development of innovative cell therapies. The company's business model revolves around leveraging its cutting-edge technologies and expertise in genetic engineering to develop personalized and off-the-shelf cell therapies for the treatment of various forms of cancer. By harnessing the power of the immune system, Legend Biotech aims to revolutionize the field of oncology and improve patient outcomes. With a focus on research and development, collaborations, and strategic partnerships, Legend Biotech is dedicated to advancing the future of cell-based immunotherapy and transforming the way cancer is treated.

Legend Biotech Corp is primarily active in the field of biotechnology.

The main competitors of Legend Biotech Corp in the market include prominent biotechnology companies such as Gilead Sciences, Inc., Celgene Corporation, and bluebird bio, Inc.

Legend Biotech Corp is a renowned biopharmaceutical company that focuses on developing cutting-edge cell therapies for patients with cancer. Founded in 2015 and headquartered in Somerset, New Jersey, Legend Biotech Corp is an affiliate of Genscript Biotech Corporation. The company primarily specializes in CAR-T cell therapies and has established a strong global presence. With a strong emphasis on research and development, Legend Biotech Corp has collaborated with numerous academic institutions and industry experts to advance the field of cell therapy. Leveraging its expertise and innovative approach, the company strives to improve the lives of patients worldwide by providing novel and effective treatments for various types of cancer.

Legend Biotech Corp has achieved several significant milestones in its trajectory. Notably, the company successfully completed a Phase 1b/2 clinical trial for its lead product candidate, LCAR-B38M CAR-T cell therapy. This innovative therapy demonstrated compelling clinical responses in patients with relapsed or refractory multiple myeloma, leading to breakthrough status designation by the U.S. FDA. Subsequently, Legend Biotech Corp went on to initiate a global Phase 2 pivotal trial for LCAR-B38M. These achievements showcase the company's dedication to advancing groundbreaking treatments for patients, solidifying its position as a frontrunner in the biotech industry.

Legend Biotech Corp is primarily present in multiple countries and regions. With its headquarters in Somerset, New Jersey, the company has an extensive global presence. It operates in key markets such as the United States, China, and Europe. Legend Biotech Corp has established strategic collaborations and partnerships to extend its reach and leverage market opportunities. By expanding its operations internationally, the company aims to capitalize on the diverse healthcare landscapes and maximize its potential for growth and innovation.

Legend Biotech Corp is a leading biopharmaceutical company that values innovation, integrity, and a patient-centric approach. With a strong corporate philosophy focused on advancing novel cell therapies, Legend Biotech Corp strives to improve the lives of patients around the world. The company is committed to developing cutting-edge treatments for oncology and autoimmune diseases, utilizing its expertise in gene and cell therapies. With a dedication to scientific excellence and a patient-first mindset, Legend Biotech Corp continues to push the boundaries of medical innovation and deliver transformative therapies to those in need.

Analysts currently set an average price target of 68.76 USD for the Legend Biotech stock (median: 72.42 USD), implying +270.7 % versus the latest price. The consensus is based on 25 analyst ratings.

Legend Biotech Analyst Price Targets 2026

25 analysts currently rate the Legend Biotech stock: 22 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Legend Biotech to generate revenue of 1.43 B USD and earnings per share of 0.04 USD.

Legend Biotech Analyst Price Targets 2026

Converted at the current exchange rate, the Legend Biotech share trades at 16.08 EUR (18.55 USD).

The Legend Biotech share (LEGN) is listed on 4 stock exchanges, including: NASDAQ (LEGN), Frankfurt (9LB.F), München (9LB.MU), Düsseldorf (9LB.DU).

Legend Biotech Corp is an innovative biotechnology company specializing in the development of cell therapies for cancer and autoimmune diseases. The company was founded in 2015 and is headquartered in Somerset, New Jersey. Its business model focuses on discovering and developing therapies for difficult-to-treat diseases, utilizing expertise in gene and cell therapy as well as a proprietary platform for designing, manufacturing, and optimizing therapy products. The company has two main divisions: cancer therapy and autoimmune therapy. In cancer therapy, Legend Biotech Corp focuses on developing immunotherapies that activate the body's immune system to destroy cancer cells, with a promising pipeline of cell therapies for various types of cancer. In autoimmune therapy, the company is developing cell therapies for diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, using a similar approach to the cancer therapy division. The company's product portfolio includes several products in various stages of clinical development, including CAR-T cell therapies for the treatment of Hodgkin's lymphoma and multiple myeloma. Legend Biotech Corp also places a strong emphasis on partnerships and collaborations, working closely with research institutions, universities, and other biotechnology companies to optimize its technology and therapy platforms and develop new products. Overall, the company's business model is characterized by innovative research and development, a focus on discovering new therapies, and close collaboration with partners and other industry stakeholders. The company is well positioned to develop and bring successful cell therapies for cancer and autoimmune diseases to the market.

The expected revenue of Legend Biotech is 1.43 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Legend Biotech is 6.63 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Legend Biotech is currently 516.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Legend Biotech stock.

The price-to-sales ratio (P/S) of Legend Biotech is currently 2.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Legend Biotech stock.

The Eulerpool Quality Score for Legend Biotech is 2/10.

The ISIN of Legend Biotech is US52490G1022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Legend Biotech is A2P5AH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Legend Biotech is LEGN. The ticker symbol is used to trade Legend Biotech shares on the stock exchange.

Legend Biotech paid dividends every year for the past 0 years.

Legend Biotech is assigned to the 'Health' sector.

The dividends of Legend Biotech are distributed in USD.

All fundamentals and in-depth analysis of Legend Biotech

Our stock analysis for Legend Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Legend Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Legend Biotech Stock
Legend Biotech Revenue→
Legend Biotech Stock
Legend Biotech Net Income→
Legend Biotech Stock
Legend Biotech P/E→
Legend Biotech Stock
Legend Biotech P/S→
Legend Biotech Stock
Legend Biotech EBIT→
Legend Biotech Stock
Legend Biotech Dividend→
Legend Biotech Stock
Legend Biotech Directors Dealings→
Legend Biotech Stock
Legend Biotech Stocks→
Legend Biotech Stock
Legend Biotech Market capitalization→
Legend Biotech Stock
Legend Biotech Debt→
Legend Biotech Stock
Legend Biotech Liabilities→
Legend Biotech Stock
Legend Biotech Equity→
Legend Biotech Stock
Legend Biotech AAQS→
Legend Biotech Stock
Legend Biotech Employees→
Legend Biotech Stock
Legend Biotech ROE→
Legend Biotech Stock
Legend Biotech ROA→
Legend Biotech Stock
Legend Biotech ROCE→
Legend Biotech Stock
Legend Biotech News→
Legend Biotech Stock
Legend Biotech Analyst Price Targets→

Health Stocks

LeMaitre VascularLDC Dental PCLLENSARLB PharmaceuticalsLENZ TherapeuticsLavipharmLeoclan CoLaurus LabsLeonaBioLaserOptek CoLepu Biopharma CoLasa SupergenericsAll Stocks A–Z →